Corrigendum to "Effect of Ca2+ and Mg2+ concentration in culture medium on the activation of recombinant factor IX produced in Chinese hamster ovary cells" [J. Biotechnol. 142 (2009) 275-278] (DOI:10.1016/j.jbiotec.2009.06.001);Effect of Ca2+ and Mg2+ concentration in culture medium on the activation of recombinant factor IX produced in Chinese hamster ovary cells

Journal of Biotechnology

Volumn 142, Issue 3-4, 2009, Pages 275-278

  Kim, Won Hee ^a   Kim, Jung Seop ^b   Yoon, Yeup ^b   Lee, Gyun Min ^a  

^a Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^b Mogam Biotechnology Research Institute   (South Korea)

Author keywords

Activation of factor IX; Calcium ions; CHO cells; Factor IX; Magnesium ions

Indexed keywords

BATCH CELL CULTURE; CELLS; CHEMICAL ACTIVATION; COSTS; CYTOLOGY; METAL IONS;

BLOOD COAGULATION; CALCIUM IONS; CHINESE HAMSTER OVARY CELLS; CHO CELL; CULTURE MEDIUM; FACTOR IX; MAGNESIUM IONS; SERUM-FREE MEDIUM;

CALCIUM COMPOUNDS;

CALCIUM ION; MAGNESIUM ION; RECOMBINANT BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9; CALCIUM; EDETIC ACID; MAGNESIUM; RECOMBINANT PROTEIN;

ANIMAL CELL; ARTICLE; BACTERIUM CULTURE; BLOOD CLOTTING; CHO CELL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CULTURE MEDIUM; DRUG SYNTHESIS; FEMALE; NONHUMAN; PRIORITY JOURNAL; SCANNING FORCE MICROSCOPY; ANIMAL; BIOSYNTHESIS; CELL SURVIVAL; CHEMISTRY; CRICETULUS; DRUG EFFECT; GENETICS; HAMSTER; METABOLISM; OVARY;

CRICETULUS GRISEUS;

ANIMALS; CALCIUM; CELL SURVIVAL; CHO CELLS; CRICETINAE; CRICETULUS; CULTURE MEDIA, SERUM-FREE; EDETIC ACID; FACTOR IX; FEMALE; MAGNESIUM; OVARY; RECOMBINANT PROTEINS;

EID: 67650064590     PISSN: 01681656     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbiotec.2009.09.011     Document Type: Erratum

References (22)

1. Bertina R.M. Elevated clotting factor levels and venous thrombosis. Pathophysiol. Haemost. Thromb. 33 (2003) 399-400
2. Dadehbeigi N., Ostad S.N., Faramarzi M.A., and Ghahremani M.H. Sex hormones affect the production of recombinant factor IX in CHO and HEK-293 cell lines. Biotechnol. Lett. 30 (2008) 1909-1912
3. Freedman S.J., Biostein M.D., Baleja J.D., Jacobs M., Furie B.C., and Furie B. Identification of the phospholipids binding site in the vitamin K-dependent blood coagulation protein factor IX. J. Biol. Chem. 271 (1996) 16227-16236
4. Gopinath S.C.B., Shikamoto Y., Mizuno H., and Kumar P.K.R. Snake-venom-derived factor IX-binding protein specifically blocks the γ-carboxyglutamic acid-rich-domain-mediated membrane binding of human factor IX and X. J. Biochem. 405 (2007) 351-357
5. Gray E., Tubbs J., Thomas S., Oates A., Boisclair M., Kemball-Cook G., and Barrowcliffe T.W. Measurement of activated factor IX in factor IX concentrates: correlation with in vivo thrombogenicity. Thromb. Haemost. 13 (1995) 675-679
6. Huang M., Furie B.C., and Furie B. Crystal structure of the calcium-stabilized human factor IX Gla domain bound to a conformation-specific anti-factor IX antibody. J. Biol. Chem. 279 (2004) 14338-14346
7. Hugenschmidt S., Planas-Bohne F., and Taylor D.M. On the toxicity of low doses of tetrasodium-ethylenediamine-tetraacetate (Na-EDTA) in normal rat kidney (NRK) cells in culture. Arch. Toxicol. 67 (1993) 76-78
8. Kasper C.K. Concentrate safety and efficacy. Haemophilia 8 (2002) 161-165
9. Kaufman R.J., Wasley L.C., Furie B.C., Furie B., and Shoemaker C.B. Expression, purification, and characterization of recombinant γ-carboxylated factor IX synthesized in Chinese hamster ovary cells. J. Biol. Chem. 261 (1986) 9622-9628
10. Kim J.M., Kim J.S., Park D.H., Kang H.S., Yoon J., Baek K., and Yoon Y. Improved recombinant gene expression in CHO cells using matrix attachment regions. J. Biotechnol. 107 (2004) 95-105
11. Morrissey J.H., Pureza V., Davis-Harrison R.L., Sligar S.G., Ohkubo Y.Z., and Tajkhorshid E. Blood clotting reactions on nanoscale phospholipid bilayers. Thromb. Res. 122 (2008) 23-26
12. Parsi K., Exner T., Connor D.E., Ma D.D.F., and Joseph J.E. In vitro effects of detergent sclerosants on coagulation, platelets and microparticles. Eur. J. Vasc. Endovasc. Surg. 34 (2007) 731-740
13. Pouplard C., Trossaert M., Querrec A.L., Delahousse B., Giraudeau B., and Gruel Y. Influence of source of phospholipids for APTT-based factor IX assays and potential consequences for the diagnosis of mild haemophilia B. Haemophilia 15 (2009) 365-368
14. 2+ Gla domain binds to a membrane through two dipalmitoylphosphatidylserines. A computational study. Biochemistry 47 (2008) 13267-13278
15. Sadagopan N.P., Li W., Cook J.A., Galvin B., Weller D.L., Fountain S.C., and Cohen L.H. Investigation of EDTA anticoagulant in plasma to improve the throughput of liquid chromatography/tandem mass spectrometric assays. Rapid Commun. Mass Spectrom. 17 (2003) 1065-1070
16. 2+ salts. Cytotechnology 32 (2000) 93-95
17. Sekiya F., Yoshida M., Yamashita T., and Morita T. Magnesium(II) is a crucial constituent of the blood coagulation cascade. J. Biol. Chem. 271 (1996) 8541-8544
18. Sharathkumar A., Hardesty B., Greist A., Salter J., Kerlin B., Heiman M., Sulkin M., and Shapiro A. Variability in bleeding phenotype in Amish carrier of haemophilia B with 31008 C → T mutation. Haemophilia 15 (2009) 91-100
19. 2+-bound Gla domain of factor IX complexed with binding protein. J. Biol. Chem. 278 (2003) 24090-24094
20. UKHCDO. Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. Haemophilia 9 (2003) 1-23
21. Urlaub G., Käs E., Carothers A.M., and Chasin L.A. Deletion of the diploid dihydrofolate reductase locus from cultured mammalian cells. Cell 33 (1983) 405-412
22. Yang Y.H., Chine D., Wu M., FitzGerald J., Grossman J.M., Hahn B.H., Hwang K.K., and Chen P.P. Novel autoantibodies against the activated coagulation factor IX (FIXa) in the antiphospholipid syndrome that interpose the FIXa regulation by antithrombin. J. Immunol. 182 (2009) 1674-1680